Why Merrimack Pharmaceuticals, Inc. Shares Skyrocketed

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of Merrimack Pharmaceuticals (NASDAQ: MACK  ) , a biopharmaceutical company developing cancer-focused therapies to be paired with companion diagnostic tests, skyrocketed as much as 74% after announcing that MM-398, its late-stage pancreatic cancer therapy that is given to patients who've previously been treated with Gemzar, had met its primary endpoint of overall survival.

So what: According to Merrimack's press release, the combination of MM-398 with 5-flouroacil and leucovorin delivered an overall survival of 6.1 months, which was an improvement of 1.9 months compared to the placebo of 5-flouroacil and leucovorin alone which achieved only 4.2 months of overall survival. Furthermore, a hazard ratio of 0.67 implied a 33% death risk reduction for the MM-398 intent-to-treat arm as well as a "significant advantage" for progression-free survival. Merrimack intends to file a new drug application for MM-398 before the year is over.

Now what: There are so few success stories among experimental late-stage pancreatic cancer drug hopefuls that it's no wonder shares exploded to the upside today. A 1.9 month survival improvement may not seem like much, but its death risk reduction of 33% is significant, and we have to remember MM-398 would only be used as a second-line therapy for patients that have stopped responding to or had no response from Gemzar. While great news for shareholders, it's also difficult to say how successful MM-398 will ultimately be. Peak sales could hit somewhere around $800 million, but that will depend largely on how well Merrimack hands the launch (if approved). Following today's monstrous run, I'd still prefer to stick to the sidelines with Merrimack.

Merrimack shares may have soared today, but they'll likely be hard-pressed to keep up with this top stock over the long haul
Give me five minutes and I'll show how you could own the best stock for 2014. Every year, The Motley Fool's chief investment officer hand-picks 1 stock with outstanding potential. But it's not just any run-of-the-mill company. It's a stock perfectly positioned to cash in on one of the upcoming year's most lucrative trends. Last year his pick skyrocketed 134%. And previous top picks have gained upwards of 908%, 1,252% and 1,303% over the subsequent years! Believe me, you don't want to miss what could be his biggest winner yet! Just click here to download your free copy of "The Motley Fool's Top Stock for 2014" today.


Read/Post Comments (4) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On May 01, 2014, at 1:04 PM, FrankoJames wrote:

    Only if Alf wins The World Cup. Fool on...

  • Report this Comment On May 01, 2014, at 1:06 PM, FrankoJames wrote:

    P.S. My last comment was posted on the wrong board. Enjoy.

  • Report this Comment On May 01, 2014, at 2:00 PM, z9841 wrote:

    At this stage, the risk of investment in Merrimack is a lot smaller than in a biotech companies that are at earlier development stages. At lower risk and an estimated peak sales of $800 million for a company with a market cap of $700 million the reward in keeping the stocks is likely drive the stock price to a high level.

  • Report this Comment On May 01, 2014, at 3:03 PM, kirovs wrote:

    I would second what z9841 is saying. I did not see in your blog any analysis on the downside, what are the chances of approval, etc.

    Even at 100-200M sales the upside for this company is pretty impressive, don't you think?

    How achievable is this number?

    I would like to see some analysis on what uptake there might be, potential pricing, etc.

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2939411, ~/Articles/ArticleHandler.aspx, 9/2/2014 10:13:47 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Apple's next smart device (warning, it may shock you

Apple recently recruited a secret-development "dream team" to guarantee its newest smart device was kept hidden from the public for as long as possible. But the secret is out. In fact, ABI Research predicts 485 million of this type of device will be sold per year. But one small company makes Apple's gadget possible. And its stock price has nearly unlimited room to run for early-in-the-know investors. To be one of them, and see Apple's newest smart gizmo, just click here!


Advertisement